One in two people will develop some form of cancer in their lifetimes. Despite decades of work, one-sixth of worldwide deaths are due to cancer. High-stakes research underpinned by strong alliances are making possible new therapies, bringing new hope.

In this podcast, Julie Little (Associate Director of Strategic Alliances) and Steve Wedge (Chief Scientific Officer) of Cancer Research UK discuss their organisation’s major role de-risking oncology research. CRUK has catalysed collaborations including biotech startups and big pharmaceutical companies alike. The newly formed Cancer Research Horizons will supercharge that mission.

BTD’s Nick Palmer leads the discussion. Learn more. Give it a listen.

#podcast #startups #biotech #research #oncology #pharmaceutical #alliances

A senior project, programme and integration professional, Louise Cooper joined the BTD team several years ago and has supported some of our largest and most complex engagements with clients such as Spectris and Glatfelter. In this podcast, Louise explores the differences between integration and more general transformation programmes, and what she finds challenging and fulfilling in her integration, separation and restructuring work.

www.btd.consulting
CLICK HERE to follow us on LinkedIn

All pharmaceutical companies look to leverage their capabilities to benefit those in the World’s poorest countries. Novartis aims to go beyond corporate philanthropy to create a more sustainable therapy-development model. By marshalling partnerships and its own people, Charlie Bailey leads Novartis teams pursuing development initiatives addressing better-known conditions like malaria, as well as more obscure ones like leishmaniasis. These initiatives can span a decade or more taking therapies through Phase I, II and III clinical trials, then ensuring the infrastructure and skills to offer them in the world’s most remote locations.

In this fascinating podcast, Charlie discusses the ideas behind Novartis’s access-focused product partnerships with BTD partner, Nick Palmer. Charlie explains how this new model offers a more sustainable path to addressing suffering in the Third World. Working with NGOs ranging from the Wellcome Trust and the Gates Foundation, to specialised ones like DNDi and MMV, Novartis is charting a course to bring First World therapies to the Third world, AND to push the boundaries of pharmaceutical innovation. He discusses specific examples and experiences to highlight this exciting approach.

CLICK HERE to follow us on LinkedIn
www.btd.consulting